Fig. 3From: An economic evaluation of eptinezumab for the preventive treatment of migraine in the UK, with consideration for natural history and work productivitySelf-reported migraine-related impairment of work productivity in the full DELIVER population (2–4 prior treatment failures) over 24 weeks, by administered treatmentBack to article page